Search
Palucorcel
go.drugbank.com/drugs/DB17955InvestigationalDeveloped by Janssen Biotech, it is being investigated for the treatment of various conditions such as amyotrophic lateral sclerosis (ALS) and macular degeneration.
AI-850
go.drugbank.com/drugs/DB05842ExperimentalAI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Adrenomedullin
go.drugbank.com/drugs/DB19102InvestigationalAdrenomedullin is under investigation in clinical trial NCT06072118 (Adrenomedullin for CADASIL).
Categories: Compounds used in a research, industrial, or household settingSB-249553
go.drugbank.com/drugs/DB05285ExperimentalIt is also under by GlaxoSmithKline to treat melanoma and lung cancer.
Ordopidine
go.drugbank.com/drugs/DB05196InvestigationalACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects … ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
Calcitonin gene-related peptide
go.drugbank.com/drugs/DB06379InvestigationalA 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in the brain, gut, perivascular nerves, and other tissue. ...
Levobunolol
go.drugbank.com/drugs/DB01210ApprovedA nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
Products: VISTAGAN LIQUIFILM 0.5%O KPropantheline
go.drugbank.com/drugs/DB00782ApprovedA muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Categories: Drugs for Functional Gastrointestinal DisordersTriplizumab
go.drugbank.com/drugs/DB30669Investigationaltriplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized
Matuzumab
go.drugbank.com/drugs/DB05101InvestigationalIt has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.